In our production sites we mill a broad range of drug substances in multipurpose equipment with proven experience.
We are equipped with containment solutions (Glove- and Half Suit Boxes) to mill highly potent ingredients.
This product category can be processed thanks to dedicated micronization lines.
In our production sites, excipients are milled in GMP equipment. The food ingredients are processed in dedicated lines with the same standard we are used to apply to pharmaceuticals.
For more than 40 years, never ceasing to invest in research and in new contents on Micronization, in a much wider and integrated approach, has always been the sense of our job. Understanding and discerning evolving needs is a foremost task for a company providing services like ours.
We provide to our customers micronization and milling services with a deep experience in the particle size reduction.
The simultaneous micronization of at least two compounds improves powder properties and skip potential blending steps.
We are equipped with containment isolators, as part of a systematic approach to control the safe handling for potent compound.
With product conditioning we are able to resolve post micronization morphological issues.
Before the Process Validation activity, we support our customers with an approach to QbD by the identification of the Critical Process Parameters (CPP), to be studied during the following Design of Experiment (DoE) development step.
We provide to our customers particle size reduction by jet milling to very low temperature, for those compounds with a low brittleness and tacky, elastic polymers or semi-solid in nature. It is also used to prevent the degradation of highly sensitive products, to avoid polymorphic changes and to avoid any increase in amorphous particles.
We provide services for PSD analysis and related activities as method development, method validation, method transfer, etc. with our cutting-edge equipment.
Over time, our customers have requested newer and newer services depending on the market complexity. We have always worked embracing a concept of recognition and acceptance of Problem Solving, in a broad and factual sense. We have often been innovators in found and implemented solutions.
We guarantee a full confidentiality to our customers which rely on us as part of the development of new compounds.
The company, firmly in the hands of the founder’s second generation, continues along the path of complete independence able to ensure flexibility and avoid any conflict of interest towards its clients.
We ensure our customers having created a system of prevention and recovery from potential threats to the company.
We accompany our clients with expertise, supporting them with regular consulting services for each step of the projects.
We consider our expertise and experience as basic concept for a long-lasting partnership with our customers.
The milestones of our company philosophy are firmly pursued by the second generation and among them the guarantee of stability and business continuity. Elements that ensure flexibility, the respect of privacy and confidentiality of our whole profession.
We provide a smart management of the projects evaluating the overall duration of the critical path in order to save time by accomplish customer´s needs.
We accommodate the needs of our customers adapting the day-to-day shifts with the willingness and ability to readily respond to changing circumstances and expectations.
We have the capacity to recover quickly from difficulties, knowing how to face the challenges we experience every day.
We have arranged a significant investment plan in our production sites that will entrain the doubling of our production and Micronization capacity. This decision was made to guarantee better and more performing lead times toward a market demanding such an expertise.
The 2020 Global Drug Bioavailability Enhancement Summit will provide a holistic overview to bioavailability enhancements. 2020’s Summit covers everything from large molecules to small molecules. We are happy to invite you during the New York NY Summit, The New Yorker, A Wyndham Hotel (January 28-29, 2020). Please, for more information check the website https://curtiscoulter.com/2020-global-drug-bioavailability-enhancement-summit/agenda/. See …
We will be pleased to welcome you at our exhibition booth during the 30th CPhI Worldwide in Frankfurt, Germany (5 – 7 November 2019). MUnit, your partner for the micronisation of API’s and High Potent Materials, will be pleased to welcome you at Booth 40B10. Please, check our video invitation below and visit us at …
MUNIT announces its participation at the 6th Controlled and Modified Drug Release Summit (August 27th – 29th 2019) in Philadelphia and the 9th American DDF Summit in Boston, September 9th – 10th 2019. Our sales team would be delighted to welcome you at our booth.
We will be pleased to welcome you at our exhibition booth during the 5th Annual Formulation & Drug Delivery Congress in London (29 – 30 April 2019) and the Respiratory Drug Delivery Europe congress 2019 in Lisbon, Portugal, May 7-10, 2019.
Mr. Maurizio Schiavazzi
Chief Commercial Officer
Mr. Giovanni Frigerio
Chief Scientific Officer
Ms. Katia Zocca
Mr. Uwe Heidenreich
Business Development Manager
Mr. Massimo Dal Bosco
Business Development Manager
Via Crocicchio Cortogna 6
T. +41 (0)91 910 30 80